MX2023006972A - Compuestos antagonistas de h4. - Google Patents

Compuestos antagonistas de h4.

Info

Publication number
MX2023006972A
MX2023006972A MX2023006972A MX2023006972A MX2023006972A MX 2023006972 A MX2023006972 A MX 2023006972A MX 2023006972 A MX2023006972 A MX 2023006972A MX 2023006972 A MX2023006972 A MX 2023006972A MX 2023006972 A MX2023006972 A MX 2023006972A
Authority
MX
Mexico
Prior art keywords
sup
antagonist compounds
ameliorating
disclosures
receptors
Prior art date
Application number
MX2023006972A
Other languages
English (en)
Inventor
Giles Albert Brown
Miles Stuart Congreve
Mark Pickworth
Charlotte Fieldhouse
Malken Bayrakdarian
Nigel Alan Swain
Barry Teobald
Delphine Karila
Daniel Beaudion
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of MX2023006972A publication Critical patent/MX2023006972A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción en la presente se relaciona a compuestos novedosos de la fórmula (1): y sales de los mismos, en donde Y, Z, R1 , R2 , R3 , R4 , R5 y n son definidos en la presente, y su uso en tratar, prevenir, mejorar, controlar o reducir el riesgo de trastornos asociados con los receptores de H4. (ver formula 1).
MX2023006972A 2020-12-14 2021-12-14 Compuestos antagonistas de h4. MX2023006972A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2019667.1A GB202019667D0 (en) 2020-12-14 2020-12-14 H4 antagonist comnpounds
PCT/GB2021/053286 WO2022129890A1 (en) 2020-12-14 2021-12-14 H4 antagonist compounds

Publications (1)

Publication Number Publication Date
MX2023006972A true MX2023006972A (es) 2023-07-31

Family

ID=74188996

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006972A MX2023006972A (es) 2020-12-14 2021-12-14 Compuestos antagonistas de h4.

Country Status (11)

Country Link
EP (1) EP4259637A1 (es)
JP (1) JP2023552888A (es)
KR (1) KR20230118921A (es)
CN (1) CN116848125A (es)
AU (1) AU2021404140A1 (es)
BR (1) BR112023011749A2 (es)
CA (1) CA3205015A1 (es)
GB (1) GB202019667D0 (es)
IL (1) IL303598A (es)
MX (1) MX2023006972A (es)
WO (1) WO2022129890A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2493888B1 (en) * 2009-10-29 2016-04-06 GlaxoSmithKline LLC Bicyclic pyridines and analogs as sirtuin modulators
AU2013344552B2 (en) * 2012-11-16 2018-03-15 Xiaoling Chen Novel heterocyclic derivatives as modulators of kinase activity
WO2018023029A1 (en) * 2016-07-28 2018-02-01 Mayo Foundation For Medical Education And Research Small molecule activators of parkin enzyme function

Also Published As

Publication number Publication date
AU2021404140A1 (en) 2023-07-27
IL303598A (en) 2023-08-01
BR112023011749A2 (pt) 2023-10-31
EP4259637A1 (en) 2023-10-18
JP2023552888A (ja) 2023-12-19
CN116848125A (zh) 2023-10-03
CA3205015A1 (en) 2022-06-23
KR20230118921A (ko) 2023-08-14
GB202019667D0 (en) 2021-01-27
WO2022129890A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
MX2022011333A (es) Compuestos moduladores de gpr52.
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
MX2022005111A (es) Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).
MX2023007192A (es) Inhibidores de prmt5.
GEP20237568B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
MX2017010062A (es) [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
NZ701559A (en) Compositions comprising povidone-iodine
SE0202462D0 (sv) Novel use
HK1138265A1 (en) Materials and methods for treating coagulation disorders
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
NZ582284A (en) Carbamoyl-cyclohexanes for treating acute mania
MX2021006029A (es) Pamoato de ketamina y su uso.
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2023001298A (es) Combinaciones para el tratamiento de cancer.
MX2022000812A (es) Metodos de tratamiento de hiperplasia suprarrenal congenita.
MX2022009243A (es) Moduladores de la via de respuesta integrada al estres.
SE0302756D0 (sv) Novel Compounds
PH12019501566A1 (en) Amide compounds and use thereof
MX2023009285A (es) Compuestos novedosos.
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.
MX2023003631A (es) Indazoles a manera de inhibidores de cinasa 1 progenitora hematopoyetica (hpk1) y metodos de uso de los mismos.
MX2023006972A (es) Compuestos antagonistas de h4.
MX2023003332A (es) Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades.